Pileri Alessandro, Cavicchi Martina, Bertuzzi Clara, Righi Simona, Zengarini Corrado, Sabattini Elena, Roncador Giovanna, Agostinelli Claudio
Dermatology Unit, IRCCS Policlinico Sant'Orsola, 40138 Bologna, Italy.
Dermatology Unit, Department of Experimental Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.
Diagnostics (Basel). 2022 Jun 29;12(7):1582. doi: 10.3390/diagnostics12071582.
Mycosis fungoides (MF) and Sezary syndrome (SS) are the two most common type of cutaneous T-cell lymphoma (CTCL). Currently, no markers can be clearly related to prognosis or to differential diagnosis between early stages and inflammatory benign diseases (IBD). The thymocyte selection-associated high mobility group box factor (TOX), has been proposed as a possible marker in differential diagnosis between early CTCL stages and IBD. Recently TOX has been related to prognosis. We aimed to investigate whether TOX may be a diagnostic or prognostic marker. MF and SS biopsies between 2010 and 2020 were retrieved. New tissues slides were stained with an anti-TOX antibody, (Clone NAN448B). On each slide, 5 fields were examined at high magnification (400×), to evaluate the percentage of marker-positivity in a quantitative way. Thirty-six patients (12 females and 24 males) and 48 biopsies were collected. Nine patients had multiple biopsies. TOX expression in MF/SS cases showed an increase from early to advanced phases. TOX was not regarded as a prognostic marker due to the absence of significant changes by comparing early MF cases with reactive conditions. TOX statistical significance increased in patients alive with disease and in those dead of disease ( = 0.013 and = 0.0005, respectively) as compared with patients in complete remission. Our results show that TOX should be regarded more as a prognostic than a diagnostic marker.
蕈样肉芽肿（MF）和塞扎里综合征（SS）是皮肤T细胞淋巴瘤（CTCL）最常见的两种类型。目前，尚无标志物能明确与预后相关，也无法用于早期阶段与炎症性良性疾病（IBD）的鉴别诊断。胸腺细胞选择相关高迁移率族框因子（TOX）已被提议作为CTCL早期阶段与IBD鉴别诊断的一种可能标志物。最近，TOX与预后相关。我们旨在研究TOX是否可能是一种诊断或预后标志物。检索了2010年至2020年间的MF和SS活检样本。新的组织切片用抗TOX抗体（克隆号NAN448B）进行染色。在每张切片上，以高倍镜（400×）检查5个视野，以定量评估标志物阳性率。共收集了36例患者（12名女性和24名男性）的48份活检样本。9例患者有多次活检。MF/SS病例中TOX的表达从早期到晚期呈增加趋势。由于早期MF病例与反应性疾病状态相比无显著变化，因此TOX未被视为预后标志物。与完全缓解的患者相比，带病生存患者和死于疾病患者中TOX的统计学意义增加（分别为=0.013和=0.0005）。我们的结果表明，TOX应更多地被视为一种预后标志物而非诊断标志物。
